Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation

This study has been completed.
Novartis Pharmaceuticals
Information provided by:
University of California, Los Angeles Identifier:
First received: September 12, 2005
Last updated: July 12, 2010
Last verified: May 2007

The purposes of this study are:

  • To review past clinical use of mycophenolate mofetil (MMF) in kidney transplant patients;
  • To discover why doses were modified and how those modifications affected the survival and health of the transplanted kidney; and
  • To determine whether, therefore, the side effects of MMF that result in dose alterations are related to outcome.

Kidney Diseases

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation

Resource links provided by NLM:

Further study details as provided by University of California, Los Angeles:

Enrollment: 651
Study Start Date: April 2006
Study Completion Date: May 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Data from existing medical records of 651 UCLA patients who received a kidney transplant, between the dates of January 1, 1995 - December 31st, 2003 All data was reviewed and analyzed as part of this study.

Inclusion Criteria:

  • Renal transplant recipients of either a cadaveric or living donor kidney.
  • 18 years of age or older.

Exclusion Criteria:

  • Multiple organ transplant recipients.
  • Prior kidney transplant recipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00203671

Sponsors and Collaborators
University of California, Los Angeles
Novartis Pharmaceuticals
Principal Investigator: Alan H Wilkinson, MD University of California, Los Angeles
Study Chair: Ralph Barbeito, Ph.D. Novartis Pharmaceuticals
  More Information Identifier: NCT00203671     History of Changes
Other Study ID Numbers: 04-05-018-01
Study First Received: September 12, 2005
Last Updated: July 12, 2010

Keywords provided by University of California, Los Angeles:
Mycophenolate Mofetil
Kidney Transplantation

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Mycophenolic Acid
Mycophenolate mofetil
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017